Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.37 |
| ▸ | JAK1 | P23458 | 6/20 | 0.35 |
| ▸ | JAK3 | P52333 | 9/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.33 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | FGR | P09769 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243514 | 0.75 | JAK2 (0.55) | JAK2JAK1JAK3PAK4CCNA2 | |
| SCHEMBL2244696 | 0.74 | ACVR1 (0.43) | JAK2JAK1JAK3PAK4AURKA | |
| SCHEMBL2189568 | 0.73 | JAK2 (0.58) | JAK2JAK1JAK3PAK4CCNA2 | |
| SCHEMBL2243801 | 0.73 | JAK2 (0.68) | JAK2JAK1JAK3PAK4AURKA | |
| SCHEMBL2247740 | 0.73 | JAK2 (0.68) | JAK2JAK1JAK3PAK4AURKA | |
| SCHEMBL4019999 | 0.73 | PAK4 (0.54) | JAK2JAK1JAK3PAK4CDK5 | |
| SCHEMBL3265610 | 0.72 | JAK2 (0.44) | JAK2JAK1JAK3PAK4AURKA | |
| SCHEMBL1396069 | 0.70 | JAK2 (0.42) | JAK2JAK1JAK3PAK4AURKA | |
| SCHEMBL25214598 | 0.69 | ACVR1 (0.45) | JAK2JAK1JAK3PAK4ADORA2A | |
| SCHEMBL2248196 | 0.69 | JAK2 (0.40) | JAK2JAK1JAK3PAK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| WO-2010038060-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.